Different Doses of Naronapride vs. Placebo in Gastroparesis - Trial NCT05621811
Access comprehensive clinical trial information for NCT05621811 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dr. Falk Pharma GmbH and is currently Recruiting. The study focuses on Gastroparesis. Target enrollment is 320 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dr. Falk Pharma GmbH
Timeline & Enrollment
Phase 2
Jan 03, 2023
Apr 01, 2025
Primary Outcome
Change in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index - Daily Diary total score from baseline to week 12
Summary
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II
 dose-finding trial. The trial will be conducted with four treatment groups in the form of a
 parallel group comparison and will serve to compare oral treatment with daily doses of 10,
 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05621811
Non-Device Trial